CytomX Therapeutics, Inc. (FRA:6C1)

CytomX Therapeutics Statistics

Total Valuation

FRA:6C1 has a market cap or net worth of EUR 625.26 million. The enterprise value is 506.53 million.

Market Cap	625.26M
Enterprise Value	506.53M

Important Dates

The next estimated earnings date is Friday, March 6, 2026.

Earnings Date	Mar 6, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	169.44M
Shares Outstanding	n/a
Shares Change (YoY)	+41.04%
Shares Change (QoQ)	+27.84%
Owned by Insiders (%)	0.52%
Owned by Institutions (%)	69.45%
Float	131.77M

Valuation Ratios

The trailing PE ratio is 26.18.

PE Ratio	26.18
Forward PE	n/a
PS Ratio	6.46
PB Ratio	6.83
P/TBV Ratio	6.92
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 20.88, with an EV/FCF ratio of -8.21.

EV / Earnings	21.21
EV / Sales	5.18
EV / EBITDA	20.88
EV / EBIT	25.33
EV / FCF	-8.21

Financial Position

The company has a current ratio of 3.64, with a Debt / Equity ratio of 0.05.

Current Ratio	3.64
Quick Ratio	3.54
Debt / Equity	0.05
Debt / EBITDA	0.20
Debt / FCF	-0.08
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is 66.76% and return on invested capital (ROIC) is 29.02%.

Return on Equity (ROE)	66.76%
Return on Assets (ROA)	9.78%
Return on Invested Capital (ROIC)	29.02%
Return on Capital Employed (ROCE)	19.83%
Revenue Per Employee	807,064
Profits Per Employee	198,998
Employee Count	121
Asset Turnover	0.76
Inventory Turnover	n/a

Taxes

In the past 12 months, FRA:6C1 has paid 209,666 in taxes.

Income Tax	209,666
Effective Tax Rate	0.87%

Stock Price Statistics

The stock price has increased by +276.00% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+276.00%
50-Day Moving Average	2.96
200-Day Moving Average	1.82
Relative Strength Index (RSI)	62.24
Average Volume (20 Days)	831

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	8.15

Income Statement

In the last 12 months, FRA:6C1 had revenue of EUR 96.85 million and earned 23.88 million in profits. Earnings per share was 0.20.

Revenue	96.85M
Gross Profit	96.85M
Operating Income	19.81M
Pretax Income	24.09M
Net Income	23.88M
EBITDA	20.90M
EBIT	19.81M
Earnings Per Share (EPS)	0.20

Balance Sheet

The company has 122.41 million in cash and 4.77 million in debt, giving a net cash position of 117.64 million.

Cash & Cash Equivalents	122.41M
Total Debt	4.77M
Net Cash	117.64M
Net Cash Per Share	n/a
Equity (Book Value)	91.53M
Book Value Per Share	0.55
Working Capital	92.21M

Cash Flow

In the last 12 months, operating cash flow was -61.58 million and capital expenditures -84,378, giving a free cash flow of -61.66 million.

Operating Cash Flow	-61.58M
Capital Expenditures	-84,378
Free Cash Flow	-61.66M
FCF Per Share	n/a

Margins

Gross margin is 100.00%, with operating and profit margins of 20.46% and 24.66%.

Gross Margin	100.00%
Operating Margin	20.46%
Pretax Margin	24.87%
Profit Margin	24.66%
EBITDA Margin	21.58%
EBIT Margin	20.46%
FCF Margin	n/a

Dividends & Yields

FRA:6C1 does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-41.04%
Shareholder Yield	-41.04%
Earnings Yield	3.82%
FCF Yield	-9.86%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

FRA:6C1 has an Altman Z-Score of -1.82 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-1.82
Piotroski F-Score	4